Live Chat

Trade Amgen AMGN

Amgen live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
date Close change Change (%) Open High Low

Latest news

Frances Wang 2024 Dec 23, 16:00

SPOT stock price: Spotify stock reaches all-time highs

Stocks
Frances Wang 2024 Dec 23, 16:00

DRCT stock price today: Direct Digital Holdings spikes on high-volume move

Stocks
Frances Wang 2024 Dec 23, 16:00

Stock Market Today: Dow Jones Closes Higher for Third Consecutive Day

Stocks
GDP data
Dyogenes Diniz 2024 Dec 22, 17:00

Morning Note: GDP in the UK, Spain and Canada to Shake Markets Today

Frances Wang 2024 Dec 22, 16:00

Bitcoin ETFs Experience Record Outflows Amid Crypto Market Decline

Cryptocurrencies ETFs
Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies

Info

Spread

1.66

Spread (%)

0.6301 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Thursday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-17:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

141908705280

Shares Outstanding

537532992

Earnings Date (Next)

1999-11-22

instr__dividend_date

2025-03-07

instr__ex_dividend_date

2025-02-14

instr__forward_annual_dividend_rate

9.52

instr__forward_annual_dividend_yield

0.0361

EPS

7.84

Learn more about this instrument

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments
Trustpilot
Live Chat